Maravai Lifesciences Holdings (MRVI) EBIT (2020 - 2026)

Maravai Lifesciences Holdings' EBIT history runs 7 years deep, the most recent figure standing at -$2.2 million for Q1 2026.

• In Q1 2026, EBIT rose 95.61% year-over-year to -$2.2 million; the TTM figure through Mar 2026 stood at -$168.3 million (up 36.72% YoY), while the FY2025 annual figure was -$215.3 million, up 8.64% from the prior year.
• EBIT was -$2.2 million for Q1 2026 at Maravai Lifesciences Holdings, up from -$58.8 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $180.7 million in Q2 2022 to a low of -$165.6 million in Q3 2024.
• Historically, EBIT has averaged $5.3 million across 5 years, with a median of -$13.4 million in 2024.
• The sharpest annual moves came in 2024 and 2026: EBIT tumbled 974.23% in 2024, then soared 95.61% in 2026.
• A 5-year view of EBIT shows it stood at $109.2 million in 2022, then sank by 106.54% to -$7.2 million in 2023, then plunged by 427.3% to -$37.7 million in 2024, then sank by 55.95% to -$58.8 million in 2025, then jumped by 96.33% to -$2.2 million in 2026.
• The last three EBIT figures came in at -$2.2 million (Q1 2026), -$58.8 million (Q4 2025), and -$41.0 million (Q3 2025), per Business Quant data.